Showing results (981-990 of 1,192) with videos related to
Sort By:
Pageof 120
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.Journal of Hematology & Oncology|June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsSankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.Haematologica|July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemiaThura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.American Journal of Hematology|October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsNicholas J Short, Elias Jabbour, Kiran Naqvi, et al.Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.Haematologica|April 15, 2021
A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndromeMahesh Swaminathan, Hagop M Kantarjian, Mark Levis, et al.American Journal of Hematology|May 15, 2016
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimenMichael E Rytting, Elias J Jabbour, Jeffrey L Jorgensen, et al.The Lancet. Haematology|February 5, 2024
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 studyAlex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, et al.Neurosurgery|January 30, 2024
A Novel Approach for Free, Affordable, and Sustainable Microsurgery Laboratory Training for Low- and Middle-Income Countries: University of Wisconsin-Madison Microneurosurgery Laboratory ExperienceAbdullah Keles, Alberto Acitores Cancela, Charbel K Moussalem, et al.The Lancet. Haematology|March 7, 2024
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studyAlexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, et al.Pageof 120